Overall survival (OS) of real-world patients with stage IIIb/IV non-small cell lung cancer (NSCLC) initiating epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKI) as first-line treatment in England. (January 2019) - Rigney, U.; Lock, K.; Chen, C.; Escriu, C.